Protagonist Therapeutics Quarterly Cash Flow Statement
NASDAQ: PTGXHealthcareBiotechnologyUSD
143.73+3.82 (+2.73%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Protagonist Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Protagonist Therapeutics generated $219.1 million of operating cash flow and spent $168,000 on capital expenditures. That left free cash flow of $218.9 million, a free-cash-flow margin of 102.5% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Protagonist Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 162.85M | 3.78M | -44.38M | -39.34M | -34.77M | -11.65M | 131.67M | -33.21M | -30.62M | 207.34M | 27.34M | -34.10M |
| Net Income growth (YoY) | — | — | -133.71% | — | — | -105.62% | +381.70% | — | — | — | — | — |
| Depreciation & Amortization | 397.00K | 407.00K | 376.00K | 361.00K | 304.00K | 239.00K | 118.00K | 231.00K | 241.00K | 236.00K | 248.00K | 244.00K |
| Stock-Based Compensation | 14.04M | 14.52M | 10.70M | 10.56M | 10.91M | 13.80M | 9.09M | 10.16M | 8.94M | 9.35M | 6.60M | 6.76M |
| Change in Working Capital | 2.69M | -2.18M | -8.11M | -607.00K | -5.73M | -5.21M | -6.75M | -6.19M | -6.38M | 46.96M | -426.00K | -3.83M |
| Operating Cash Flow | 219.05M | -48.94M | -36.98M | -1.94M | -28.78M | 125.36M | -29.18M | -27.86M | 268.62M | -27.43M | 16.96M | -26.61M |
| Capital Expenditures | -168.00K | -215.00K | -144.00K | -88.00K | -813.00K | -545.00K | -310.00K | -775.00K | -28.00K | -242.00K | -19.00K | -404.00K |
| Investing Cash Flow | -2.43M | 90.89M | 48.81M | -58.55M | 54.81M | -94.40M | -8.72M | -208.71M | -88.12M | 6.07M | -61.29M | -13.56M |
| Debt Issued | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Financing Cash Flow | 9.74M | 23.37M | 2.84M | 5.66M | 2.92M | 11.44M | 4.03M | 12.05M | 2.57M | 7.20M | 527.00K | 35.31M |
| Net Change in Cash | 226.37M | 65.32M | 14.68M | -54.83M | 28.95M | 42.40M | -33.87M | -224.52M | 183.07M | -14.16M | -43.80M | -4.86M |
| Free Cash Flow | 218.88M | -49.16M | -37.12M | -2.02M | -29.59M | 124.82M | -29.49M | -28.64M | 268.59M | -27.67M | 16.94M | -27.02M |
This table shows 12 quarterly periods of Protagonist Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow PTGX's reporting calendar. What is a cash flow statement?